(NASDAQ: VTRS) Viatris's forecast annual revenue growth rate of 1.65% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 134.35%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Viatris's revenue in 2025 is $14,124,400,000.On average, 12 Wall Street analysts forecast VTRS's revenue for 2025 to be $16,594,700,315,776, with the lowest VTRS revenue forecast at $15,835,683,970,128, and the highest VTRS revenue forecast at $17,212,048,967,168. On average, 12 Wall Street analysts forecast VTRS's revenue for 2026 to be $16,787,045,884,400, with the lowest VTRS revenue forecast at $15,931,280,869,504, and the highest VTRS revenue forecast at $17,479,259,577,472.
In 2027, VTRS is forecast to generate $17,112,996,758,176 in revenue, with the lowest revenue forecast at $16,081,010,952,864 and the highest revenue forecast at $18,015,984,337,824.